MedTrace Logo

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02514577 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Conditions

Interventions

DRUG

IDP-122 Lotion

Topical lotion

DRUG

IDP-122 Vehicle Lotion

Topical lotion. No active ingredient.

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Binu j Alexander · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-07
Primary Completion
2017-05-01
Completion
2017-05-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514577 on ClinicalTrials.gov